SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ----------------------------- FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2003 ORPHAN MEDICAL, INC. -------------------- (Exact name of registrant as specified in its charter) Delaware 0-24760 41-1784594 -------- ------- ---------- (State or other jurisdiction (Commission (I.R.S. employer of incorporation) file number) identification number) Suite 250, 13911 Ridgedale Drive, Minnetonka, MN 55305 (952) 513-6900 -------------- ----- -------------- (Address of principal (zip code) (Registrant's telephone executive offices) number, including area code) Not Applicable -------------------------------------------------------------------------------- (Former name or former address, if changed since last report) Item 5. Other Events. ------------- The Company announced a licensing agreement with Celltech Pharmaceuticals, a division of Celltech Group plc, for the sales and marketing rights for Xyrem(R) (sodium oxybate) oral solution in Europe. The Company received $2.5 million of initial proceeds from the transaction. This agreement was discussed in the Company's press release dated October 30, 2003. The press release is attached as Exhibit 99.1 to this Form 8-K. Item 7. Financial Statements and Exhibits --------------------------------- Exhibit 99.1 - Press release dated October 30, 2003. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 31, 2003 ORPHAN MEDICAL, INC. /s/ Timothy G. McGrath ------------------------------------- Timothy G. McGrath Chief Financial Officer (duly authorized officer and principal financial officer) EXHIBIT INDEX Exhibit Number Description 99.1 Press release dated October 30, 2003.